Cogent Biosciences, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2022 | $-28.3M | $-28.8M | $441.0K | $4.2M |
| Jun 2022 | $-26.5M | $-27.6M | $1.1M | $4.5M |
| Sep 2022 | $-34.4M | $-37.8M | $3.3M | $4.6M |
| Dec 2022 | $-29.4M | $-31.4M | $2.0M | $5.0M |
| Mar 2023 | $-39.5M | $-40.6M | $1.1M | $5.9M |
| Jun 2023 | $-32.1M | $-33.3M | $1.3M | $7.2M |
| Sep 2023 | $-38.0M | $-38.1M | $121.0K | $8.8M |
| Dec 2023 | $-44.1M | $-44.4M | $315.0K | $8.9M |
| Mar 2024 | $-52.5M | $-52.6M | $70.0K | $9.4M |
| Jun 2024 | $-42.7M | $-42.8M | $148.0K | $10.0M |
| Sep 2024 | $-52.0M | $-52.3M | $280.0K | $10.4M |
| Dec 2024 | $-60.6M | $-60.7M | $75.0K | $10.0M |
| Mar 2025 | $-66.5M | $-67.1M | $547.0K | $10.0M |
| Jun 2025 | $-54.5M | $-54.7M | $131.0K | $9.7M |
| Sep 2025 | $-64.3M | $-64.4M | $65.0K | $10.6M |
| Dec 2025 | $-79.1M | $-79.9M | $811.0K | $15.8M |
| Mar 2026 | $-86.9M | $-87.3M | $449.0K | $16.9M |
| Jun 2026 | $-77.3M | $-77.6M | $370.0K | $17.1M |